European office withdraws Nexium patent

Dec 21, 2006

The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.

AstraZeneca officials said they were disappointed with the patent office's decision, but had other patents and intellectual property measures that protected the drug in Europe, the Wall Street Journal said. The ruling involved the drug's chemical composition. The patent was due to expire in 2014.

The generic drug maker Ratiopharm International GmbH of Germany challenged the patent, which led to the EPO's decision. Ratiopharm has not indicated its plans regarding a generic form of Nexium.

Generic drug makers are challenging Nexium's patents in the United States.

AstraZeneca said Nexium's $4.6 billion in worldwide sales accounted for about a fifth of the company's third-quarter revenue.

Copyright 2006 by United Press International

Explore further: Rapivab approved to help treat flu

add to favorites email to friend print save as pdf

Related Stories

US Supreme Court weighs generic drug dispute

Oct 15, 2014

(AP)—The US Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.

India denies revoking Roche patent, says it lapsed

Aug 06, 2013

India on Monday denied revoking additional patents related to Roche Holding's breast cancer drug Herceptin, saying the Swiss giant failed to follow legal procedures so the applications lapsed.

Walgreen 3Q profit jumps but misses estimates

Jun 25, 2013

Walgreen Co.'s fiscal third quarter earnings jumped 16 percent, but its shares plunged Tuesday as investors fretted over sluggish sales outside the drugstore chain's pharmacies and other troubling trends.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

15 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.